Failure of critical cellular energy sensor responsible for CKD progression, study finds

Chronic kidney disease (CKD), an affliction characterized by progressive loss of kidney function, affects millions of people worldwide and is associated with multi-organ damage, cardiovascular disease, and muscle wasting. Just like engines, living cells require energy to run, thus the combined millions of cells forming an organ have huge energy requirements. Although the heart has the highest energy needs of all human organs, the kidneys come a close second. Energy depletion can result in kidney damage and the build-up of toxic compounds in the body, contributing to the progression of CKD. Currently, there is no effective treatment to halt this progression.

Adenosine triphosphate (ATP) is the major "fuel" in most living cells and is converted to adenosine monophosphate (AMP) during energy transfer. A specialized energy sensor called 5ʹ-AMP-activated protein kinase  (AMPK) detects even the slightest changes in cellular energy by sensing AMP levels, triggering the production of ATP in response to energy depletion. However, AMPK activity is decreased in CKD and the mechanism controlling this dysregulation is unclear.

Now, a research team from TMDU and Kyushu University has shown that failure to sense AMP is the key mechanism underlying the inactivity of AMPK in CKD. In a recent study published in Kidney International, they outline how they came to this conclusion and what it may mean for CKD patients.

"Metabolites can tell us a lot about what's going on in a cell," explains lead author Hiroaki Kikuchi. "In CKD mice, metabolite profiling showed that despite high levels of AMP, there was a substantial decrease in AMPK activation, leading us to conclude that the AMP-sensing function of AMPK was defective."

Armed with this new information, the researchers tried bypassing the AMP-sensing mechanism to determine whether AMPK could still be activated in CKD mice. By treating the mice with A-769662, an AMPK activator that binds at a different site to AMP, they could significantly attenuate CKD progression and correct associated tissue damage.

Critically, the build-up of waste products in the blood as a result of reduced kidney function was shown to be responsible for the decreased AMP-sensing activity of AMPK. "Our findings suggest that energy depletion, CKD progression, and the accumulation of toxic metabolites form a vicious cycle in CKD patients," says co-corresponding author Eisei Sohara. "However, AMPK activation via AMP-independent mechanisms can break this cycle and represents a novel therapeutic approach for the treatment of CKD."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New FDA award fuels research into autosomal dominant tubulointerstitial kidney disease